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Background: In this study we explored preeclampsia through a bioinformatics approach. We create a
comprehensive genes/proteins dataset by the analysis of both public proteomic data and text mining of public
scientific literature. From this dataset the associated protein-protein interaction network has been obtained. Several
indexes of centrality have been explored for hubs detection as well as the enrichment statistical analysis of
metabolic pathway and disease.
Results: We confirmed the well known relationship between preeclampsia and cardiovascular diseases but also
identified statistically significant relationships with respect to cancer and aging. Moreover, significant metabolic
pathways such as apoptosis, cancer and cytokine-cytokine receptor interaction have also been identified by
enrichment analysis. We obtained FLT1, VEGFA, FN1, F2 and PGF genes with the highest scores by hubs analysis;
however, we also found other genes as PDIA3, LYN, SH2B2 and NDRG1 with high scores.
Conclusions: The applied methodology not only led to the identification of well known genes related to
preeclampsia but also to propose new candidates poorly explored or completely unknown in the pathogenesis of
preeclampsia, which eventually need to be validated experimentally. Moreover, new possible connections were
detected between preeclampsia and other diseases that could open new areas of research. More must be done in
this area to resolve the identification of unknown interactions of proteins/genes and also for a better integration of
metabolic pathways and diseases.Background
Preeclampsia is a pregnancy related disease associated with
hypertension, proteinuria and increased maternal and peri-
natal morbidity and mortality, without known underlying
mechanism and preventive treatment [1,2]. On the other
hand, the future health or possible risks of women with
previous history of preeclampsia are important areas of in-
vestigation. In this direction, it is well known the increased
risk of future cardiovascular disease and renal dysfunction,
however, other risks are also being discussed [1,3-5]. Owing
to the morbidity and mortality of this pregnancy related
disease and the possible multifactorial causes involved
[1-5], several experimental procedures have been applied
by researchers in the last two decades, evidently, generating
an elevated number of unprocessed information.* Correspondence: irebelo@ff.up.pt
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reproduction in any medium, provided the orAlthough some bioinformatic analysis has been per-
formed in particular microarray assays [6,7], an extensive
data evaluation and processing has not yet been per-
formed. Furthermore, the capabilities of bioinformatics
tools for gene prioritization, network analysis, gene
ontology and gene-disease relationships [8,9], together
with all available data on protein/gene expression during
preeclampsia bring an interesting and valuable oppor-
tunity for an in-silico study of the disease. Therefore, the
present study is focused on two main areas: I) collection
and basic analysis of the genes/proteins-diseases dataset,
including, protein-protein interaction network and path-
way enrichment analysis and II) exploration of the
related gene-diseases in order to evaluate other genetic
diseases possibly related with preeclampsia.Results
Protein-protein interaction network analysis
Preeclampsia PPI network topology reveals (Figure 1) a
similar behavior with respect to general topology of PPItd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 PPI network and topology. Left) PPI network and Right) Degree distribution. The degree distribution follows a power law distribution.
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free properties. These types of networks have the par-
ticular feature that some nodes are highly connected
compared with others on the same network. These
highly connected nodes (hubs) in general, represent im-
portant proteins/genes in biological terms and therefore
are treated with special attention.
The top 50 genes with high scores and also present in
the initial set (347) are shown in Table 1, however, other
genes were found with high scores value but there are
not part of the initial gene group. As expected some of
the selected genes like FN1, FLT1, F2, VEGFA, PGF,
TNF, NOS and INHBA, are well known preeclampsia
relates genes (see discussion) and several of them are
related with signaling pathways.
A total of 27 communities (k = 3) covering 161 genes
were identified by communality analysis. In Figure 2 (Left)
we represent those communities that are superimposed
to form a large connected graph. The genes involved in
communities overlapping are also highly represented in
the Table 1 (and also the genes members of the large
community). The model based clustering analysis reveal
an optimal number of 8 clusters (BIC= 152192.4) with an
ellipsoidal distribution with equal volume, shape and vari-
able orientation. The genes are grouped in the clusters
(C1. . .8) as follow: C1 (67), C2 (56), C3 (1806), C4 (59),
C5 (133), C6 (23), C7 (95) and C8 (161). The C8 and C4
correspond with the highest mean scoring value: 393.3
and 348.9 respectively, and contain all the 100 genes with
highest score values (part or not of the initial gene set).
Furthermore, 161 genes of C8 are also the same genes
detected in the communality analysis.
Gene ontology (GO) enrichment analyses were per-
formed in all obtained clusters. However, for simplicity
only C4 and C8 are presented (Figure 2 Right). The GOanalysis reveals that C8 comprise several processes
related with angiogenesis, apoptosis and cell prolifera-
tion and also shared with C4 several processess involved
in cell activation and biological adhesion. The relation
between these processes as well as the fact that both
groups are representative of the highest scored genes
could indicate a particular relevance of the clusters in
terms of genes-disease relationship. On the other hand,
also these processes are well known involved in pree-
clampsia and are also consistent with the pathway en-
richment analysis.
Diseases and metabolic pathway enrichment analysis
Several types of diseases were found statistically signifi-
cant in the enrichment analysis; partial results are pre-
sented in Table 2. Obviously, preeclampsia and even
hypertension have to be present in the analysis. In the
GAD database there are several disease classes and be-
side the presented in Table 2, others like hematologic (p-
value = 6.1E-06) and renal diseases (p-value = 2.5E-04)
were also significant. Even when we present only the
results obtained with GAD database, analysis was also
performed with OMIN database confirming the ovarian
cancer (p-value = 0.019) and also indicating colorectal
cancer as statistically significant (p-value = 0.011), how-
ever, better results were obtained with GAD and also
more consistent with literature information and pathway
enrichment analysis.
It is important to consider that several genes in the
PPI network do not present a known relation with spe-
cific diseases, at least reported in the GAD or OMIN
databases. Only around 30% of the 2400 genes were
found in the databases. This difficulty means that we
have to be cautious with the preeclampsia genes-
diseases relationships and with the reliability of the




Entrez1 Score I Gene
symbol
Entrez1 Score I
4067 LYN 983.5136 2324 FLT4 426.74
2335 FN1 823.9037 6767 ST13 425.5747
29110 TBK1 672.1386 873 CBR1 424.257
8826 IQGAP1 635.9629 667 DST 414.0964
1759 DNM1 628.7167 9495 AKAP5 412.7567
5573 PRKAR1A 622.5864 8601 RGS20 408.6292
10397 NDRG1 590.672 2896 GRN 401.0426
2923 PDIA3 559.3358 4323 MMP14 400.1593
5339 PLEC 541.5909 55697 VAC14 394.4482
6303 SAT1 515.6939 5228 PGF 393.3167
2321 FLT1 508.3947 8553 BHLHE40 392.8039
2317 FLNB 505.1671 604 BCL6 385.7928
4221 MEN1 499.019 5054 SERPINE1 382.5547
7067 THRA 487.6884 4597 MVD 380.0219
2147 F2 482.7173 5569 PKIA 377.6185
3959 LGALS3BP 475.7565 140885 SIRPA 375.9565
10603 SH2B2 473.9241 3624 INHBA 367.5795
7422 VEGFA 465.5212 10272 FSTL3 367.2976
8815 BANF1 461.918 4846 NOS3 361.5554
23650 TRIM29 448.6764 3553 IL1B 357.2569
7124 TNF 441.7007 3880 KRT19 355.4412
904 CCNT1 440.8304 9444 QKI 354.3211
3556 IL1RAP 430.4483 8773 SNAP23 348.0265
9131 AIFM1 429.2521 27250 PDCD4 345.9363
6449 SGTA 429.1609 5291 PIK3CB 345.5114
The table shown the first 50 genes selected according to the score values and
arranged in descendent order. We also provide the gene symbol the
associated Entrez Gene identifier.
Notes: 1) Entrez gene ID.
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nificant inferences, can be made.
A similar situation occurred with the pathway enrich-
ment analysis (Table 3). Even when the KEGG database
is the most representative of our gene space and high
coherence was noticed with the physiopathology of PE,
the results only cover around 50% of the initial 2400
genes. A similar procedure was also performed with the
Reactome and BioCarta databases with a less covering
(37% and 27% respectively) and showing a high coher-
ence with Table 3 results. These databases reveal other
significant pathways like NGF, PDGF, BMP, EPO and
EGFR signaling as well as apoptosis and hemostasis
pathways (data not shown). Some cancerous pathways
(i.e. prostatic, pancreatic and lung) were also found sta-
tistically significant in KEGG but were excluded from
Table 3, in order to simplify, because many of them havesimilar reactions with the general cancer pathway,
already presented in the Table 3.
In order to simplify and enhance the understanding
of the involved pathways and their relationship with
the selected hubs, a fusion between both was made
(Figure 3). However, it is important to exalt that from
the 50 hubs previously selected; only 22 present some
significant pathway association with Table 2. The genes:
NDRG1, LGALS3BP, BANF1, SGTA, TRIM29, RGS20,
PLEC, GRN, ST13, AKAP5, FSTL3, DST, PKIA, QKI,




The top 50 genes selected were manually analyzed with
the scientific literature in order to validate its connection
with PE or even changes during pregnancy and we cor-
roborate that several of them like FLT1, FLT4, VEGFA,
PGF, TNF, FN1, F2 and NOS3 can be related to the main
lines of research in preeclampsia pathogenesis hypoth-
esis and specially angiogenesis [11-16]. Moreover, PGF,
INHBA and related inhibin as well as activin proteins
have been considered in several predictive model of PE
[17,18]. The presence of those genes in our selection
could validate the method applied and increase our con-
fidence with respect to those genes that are poorly
explored or unknown in their association with pree-
clampsia. In the latter group, we have for example the
genes LYN, PDIA3, NDRG1 and TBK1. The PDIA3
genes encode an endoplasmic protein highly related with
folding processes and in its relation with pregnancy only
one article was found [19] revealing that PDIA3 gene
intervene in trophoblast invasion via interleukin (IL) 11.
Similarly, TBK1 could also intervene during the first
moments of pregnancy to secure the implantation in re-
lation with the nuclear factor kappa B [20]. However,
there are not articles of PDIA3, TBK1 or LYN related
with preeclampsia. Moreover, only one article was found
describing an increased expression of NDRG1 during
preeclampsia [21]. A similar problem is found with other
genes such as IQGAP1, DNM1, SAT1, MEN1 and
SH2B2 that also have been little explored during
pregnancy.
Cluster analysis indicates that mainly C8 but also C4
probably embrace the most significant genes, at least
related with centrality. All genes highest scored are part
of these clusters as well as the large community graph
and as we can notice the genes that lead to a commu-
nity superposition are also highly scored in Table 1
(Figure 2). On the other hand there are other genes like
ENG, VEGFB and INHA that are well known related to
preeclampsia and are also part of the C8 cluster [11-18].
It is important to notice that there are other genes not
Figure 2 Communality and clusters analysis. Left) Representation of the largest connected community. Red nodes represent the genes
involved in communities overlapping. White nodes represent the bigger community. Right) Representation of C8 and C4 clusters and the related
statistically significant biological process obtained by gene ontology enrichment analysis.
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gene set. In this group, EGFR and GRB2, are both with
highest scores and there are both well related with
preeclampsia [22,23]. Thus, even when the work pre-
sented focused on the analysis of the initial group, it is
possible that relevant genes were identified by PPITable 2 The diseases enrichment analysis
Disease classes Disease p-value
Cancer (p-value = 1.24E-11) breast cancer 9.76E-07
ovarian cancer 4.30E-04
lupus erythematosus 4.4E-02
Cardiovascular (p-value = 4.28E-9) myocardial infarction 8.7E-09
coronary artery disease 7.38E-06
Stroke 6.16E-05
heart disease, ischemic 9.7E-03
blood pressure, arterial 8.2E-03
inflammatory bowel disease 2.9E-02




Reproduction (p-value = 7.9E-03) preeclampsia 1.29E-05
pregnancy loss, recurrent 6.08E-04
The table provides the p-value obtained from disease enrichment analysis
according to the Disease Class and also the sub-classes diseases following the
GAD database structure. The results showed are partials as discussed in the
respective section.topology but not included in the initial subset. More-
over, the GO enrichment analysis clearly reveals that C8
and C4 clusters are related with angiogenesis, apoptosis
and biological adhesion, which are also biological pro-
cesses obtained with the pathways enrichment analysis.
Angiogenesis and related processes (i.e. vascular growing,
cell differentiation and hypoxia) are considered as central
processes related to preeclampsia [24] and therefore it
could support the reliability of the procedure and also the
necessity to increase the study of the C8 and C4 genes.
Future combination of centrality indexes and specific
clusters selection together with machine learning proce-
dures or genetic algorithm optimization based on groups
differentiability or external prediction subset, could re-
duce even more the final gene space and we are cur-
rently working in this direction.
Diseases and pathway analysis
We manually evaluate through scientific literature the
connection of PE with the identified metabolic pathways
and diseases. The relationship between preeclampsia
and inflammatory, immunologic, angiogenic and
hemodynamic responses are very well documented [22-
28] and therefore are expected not only in the gene
space but also in the metabolic pathways analysis. The
metabolic pathway analysis (Table 3) indicates a strong sig-
nificance of the cancer pathway that is consistent with the
disease analysis (Table 2) and also with the VEGF signaling,
that is present in several related processes like cytokine-
cytokine receptor, angiogenesis and also cancer pathway.
Figure 3 Genes-metabolic pathways interaction. The genes and pathways were selected after hubs detection (see Table 1) and enrichment
analysis respectively (see Table 3).
Table 3 The KEGG pathway enrichment analysis
Pathway description p-value Pathway description p-value
Pathways in cancer 1.10E-42 Fc gamma R-mediated phagocytosis 2.90E-07
Focal adhesion 3.50E-29 RIG-I-like receptor signaling pathway 5.30E-07
Apoptosis 2.10E-17 Chemokine signaling pathway 5.90E-07
Neurotrophin signaling pathway 3.40E-17 Leukocyte transendothelial migration 6.20E-07
TGF-beta signaling pathway 5.10E-16 VEGF signaling pathway 8.60E-07
T cell receptor signaling pathway 8.90E-15 NOD-like receptor signaling pathway 1.20E-06
ErbB signaling pathway 1.80E-14 mTOR signaling pathway 7.00E-06
B cell receptor signaling pathway 8.70E-14 Complement and coagulation cascades 7.90E-06
Adherens junction 2.00E-12 Tight junction 1.10E-05
Fc epsilon RI signaling pathway 3.60E-12 RNA polymerase 1.60E-05
ECM-receptor interaction 6.80E-12 Ubiquitin mediated proteolysis 2.20E-05
Insulin signaling pathway 3.00E-10 GnRH signaling pathway 1.10E-04
Regulation of actin cytoskeleton 3.10E-09 Hematopoietic cell lineage 1.20E-04
Toll-like receptor signaling pathway 1.01E-08 Cytokine-cytokine receptor interaction 2.00E-04
Wnt signaling pathway 1.10E-08 Hedgehog signaling pathway 3.70E-04
Cell cycle 1.50E-08 Natural killer cell mediated cytotoxicity 3.80E-04
MAPK signaling pathway 1.50E-08 Cytosolic DNA-sensing pathway 6.70E-04
Adipocytokine signaling pathway 7.50E-08 Notch signaling pathway 2.60E-03
Progesterone-mediated oocyte maturation 2.50E-07 Renin-angiotensin system 1.80E-02
The table provides the p-value obtained from pathway enrichment analysis in the KEGG database. The pathways names correspond with the KEGG nomenclature.
The results showed are partials as discussed in the respective section.
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plification of the metabolic pathways was possible, however,
more needs to be done in this area in order to better inte-
grate not only the hubs genes but also the comprehensive
data created by the PPI interaction.
Considering the associated metabolic pathways we can
notice that several signaling pathways are statistically sig-
nificant and some of them are connected with PIK3CB,
LYN and linked in several cases with TNF (Figure 3)
that is a central gene affecting several processes and also
widely studied in its relation with preeclampsia [28].
Similarly, SH2B2 that encodes an adapter protein of sev-
eral tyrosine kinase receptors is also connected with
metabolic pathways indirectly related with apoptosis.
Contrasting PDIA3 and NDRG1 are not present in the
Figure 3 connected with any metabolic pathway, but the
recent relation found between PDIA3 and IL11 could
open a relationship with cytokine-cytokine receptors
[19], specifically through the hematopoietins receptor
family. We can also notice (Figure 3 and Table 3) that in
the pathways associated with central proteins (the hubs),
those highly connected are the cytokine-cytokine recep-
tors, focal adhesion and apoptosis pathways and they
contain almost the complete space of genes mainly stud-
ied in preeclampsia.
The elevated number of signaling pathways that we
found statistically significant, together with the hubs dis-
tribution detected in Table 1, seems to point out the idea
of a signaling related disease similar to cancer, however,
the apoptosis and angiogenic mechanism had been
related previously with PE and are also highly repre-
sented in our study.
On the other hand, the relationship between PE and
cardiovascular diseases is well known. Women with pre-
vious history of PE or even pregnancy hypertension
present an increased risk of future development of car-
diovascular disease or hypertension [29-31]. This is
clearly expressed in our results (Table 2). Moreover, our
results also suggest a significant relationship between
cancer and PE (at this point it is not possible to say if
this correlation is positive or negative) indicated by dis-
eases enrichment analysis and also by the metabolic
pathways. However, the experimental and epidemio-
logical evidence that could support the influence of PE
in future cancer development is for now inconclusive,
even when could be reasonably expected by the wide
kind of genes that are actually shared between both dis-
eases (i.e. angiogenesis related genes). Several articles re-
port a reduced risk of future cancer development in
women with previous history of PE, but others could not
find any statistical relationship [32-35].
There are neither clinical signs in common between PE
and Alzheimer and nor epidemiological studies. However,
the connection between both diseases has been questionedbefore (at least in late-onset Alzheimer's disease) [36] and
was significant in the present study. Therefore, although it
is not possible to validate our findings experimentally with
the current information, it actually opens new possibilities
for future works. A similar problem concerns to other age-
ing related factors like atherosclerosis, arthritis or longev-
ity (that for obvious reasons will be difficult to explore in
PE during long-term studies).
The present study points out several advantages of the
bioinformatics analysis but some limitations were also
found. The detection of genes that are very well known
to be involved in PE thought the applied methodology as
well as the consistence of the results across metabolic
information could support the novel candidates found,
however, it is necessary to reduce even more the genes
space applying other methodologies as well as to design
new experimental experiences. On the other hand, the
limitation of the human protein interaction information
suggests that also orthologous genes should be needed
in order to increase the PPI covering of the initial data-
set and to increase the capabilities of the metabolic
pathways and disease enrichment analysis.Conclusions
In the present study we applied several bioinformatics
tools in order to create a comprehensive initial database
of genes statistically related to preeclampsia and a fur-
ther expansion through the construction of related
protein-protein interaction network. Using several cen-
trality indexes for hubs detection, some well know pree-
clampsia related genes like FLT1, TNF, VEGFA and PGF
were detected as well as other genes with high scores,
like PDIA3, NDRG1, TBK1, LYN, IQGAP1, DNM1,
SAT1, MEN1 and SH2B2 that have been poorly explored
or unknown in the current state of the art of preeclamp-
sia physiopathology.
Through disease enrichment analysis we corroborated
the well know connection between PE and cardiovascular
disease, but we also found a possible link of PE with
aging and cancer. Moreover we also found the cancer
pathway, focal adhesion, ECM-receptor interaction, apop-
tosis and cytokine-cytokine receptors interactions meta-
bolic pathways highly represented by the PPI network that
are in agreement with some of the preeclampsia-diseases
relationship found, as well as with the central topics of
the current preeclampsia investigations.Methods
Dataset construction
Experimental proteomic/genomic data comparing nor-
mal (N) and preeclamptic (PE) pregnancies was obtained
analysing the Gene Expression Omnibus (GEO) database
[37]. The datasets considered are represented in Table 4.
Table 4 GEO data used for dataset construction
GEO Sample Method Collection
(Weeks)
Tissue Ref.
GSE6573 10(PE), 10(N) Affymetrix At delivery Placenta [25]
GSE47071 10(PE), 4(N) Agilent See notes Placenta [6]
GSE25906 23(PE), 37(N) Illumina 27-38 Placenta [26]
GSE147222 12(PE), 11(N) Affymetrix See notes Placenta [27]
GSE10588 17(PE), 26(N) ABI Human At delivery Placenta [38]
The Table shown the GEO data sources, references and complementary
information used in the study.
Notes: 1) The 10 samples were collected for placenta biopsy during delivery.
Five of the preeclamptic samples were collected before 31 weeks of gestation
and the rest after this time. 2) The 23 samples were collected for placenta
biopsy during delivery, however, because in GEO appear two platform types,
both were analysed.
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to reduce the number of genes. In our case we consid-
ered an adjusted p-value ≤0.05 and a fold expression ≥2
as discussed elsewhere [6,7,25-27,38,39]. Initially the
p-value was obtained by a bootstrapping procedure with
1000 or 10000 iterations (depending on size of the
sample) obtaining 645 statistically significant modulated
genes, however, applying the false discovery rate (FDR)
correction by the Benajmini-Hochberg method [40], this
sample was reduced to 330 genes.
In addition, several text mining exploration tools were
used to complement the GEO results. There are several
tools to perform a text data mining analysis but several
of them require extra information (i.e. chromosome re-
gion) instead phenotype or diseases notation (i.e. dis-
eases name or related keywords). In our case we choose
those methods that do not require previous genetic
knowledge of the disease [8]. Moreover, the text mining
procedures usually could provide several false positive
associations and therefore those tools which also com-
bine text-mining with other data sources in the analysis
are preferred [8,41]. Considering these aspects, we used
the following tools: PolySearch [42], Candid [43] and
Phenopred [44]. Candid and PhenoPred use several het-
erogeneous data sources to overcome bias while in Poly-
Search analyse was restricted to PubMed publications.
Obviously many other algorithms could be used in alter-
native. In order to reduce the risk of including biased
relationships, the top 10–20 genes/proteins with the
highest scores were selected and individually analyzed
considering the preeclampsia related scientific publica-
tions. Some of the top genes were also present in the
previous dataset (GEO), therefore, the final dataset con-
tained 347 genes.Protein-protein interaction network (PPI)
The proteins associated with the previous 347 genes
were identified and cross-referenced with the IRefIndex(v1.16) [45] and a signaling curated databases [46] that
were used to create the protein-protein interaction (PPI)
network. The IRefIndex database provide an index of
protein interactions available in several databases like:
BIND, BioGRID, DIP, HPRD that simplify the task con-
suming process of inter-database mapping and lead to a
comprehensive covering of the available known protein
interactions space. On the other hand, this PPI database
is easily integrated in Cytoscape. Additionally, many dis-
eases are related with signaling pathways modifications
and therefore the inclusion of this interaction database
considerable improve the PPI space. The interaction
search was restricted to Homo Sapiens and includes all
kind of experimental procedure as well as some predict-
ive interactions (mainly from the OPHID database). The
curation of the final database was performed both,
manually and using home-made software to remove du-
plicate interactions and unify isoforms notation with
unique genes. We obtained our final PPI network with
3279 interactions and 2400 nodes.
Some of the proteins present in our initial dataset had
not any known experimental interaction (at least in
humans) and therefore the 2400 nodes cover only 234
(67.45%) genes of the initial set (347). The network
visualization and network topology indexes, calculated
in the hubs detection process, were carried out using
Cytoscape 2.8.2 and CytoHubba [47,48].
Several methodologies are available for hubs and es-
sential genes identification, and all of them with the re-
spective advantage and limitations [47,49-54]. Some
strategies are the use of genetic algorithm or machine
learning procedures [49,50], however, the centrality
approaches are by far the most applied procedures even
by simplicity and because several studies had being
pointed out its applicability [47,51,52]. Therefore, several
centrality indexes were evaluated: Betweenness, bottle-
neck, density of maximum neighborhood component
(DMNC), node degree, edge percolation component
(EPC), eccentricity, maximal clique centrality (MCC),
maximum neighborhood component (MNC), radiality
and stress [47]. On the other hand, to obtain a scoring




1 max Icið Þ  Ici





Where Ici is the values of centrality indexes and
i = 1. . .Nc, and is the number of calculated centrality in-
dexes (Nc = 10). As we can note, score I is the sum of all
the indexes percent value after individual normalization
and therefore is restricted to a maximal value of 100×Nc
which simplify even better the top genes selection. With
the normalized centrality indexes we also performed a
model-based clustering analysis using R-package [53] in
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ity ranks. We also performed a communality (or cliques)
network analysis by clique percolation method using
CFinder [54]. The communality analysis provides a bet-
ter topology description of the network including the lo-
cation of highly connected sub-graphs (cliques) and/or
overlapping modules that usually correspond with rele-
vant biological information.
Pathway and diseases enrichment analysis
The pathways and diseases enrichment analysis were
performed through the DAVID bioinformatics resource
6.7 [55], exploring the well know databases: KEGG,
BioCarta and Reactome (pathways related) as well as
OMIN and Genetic Association Database (GAD) (dis-
eases related analysis). This online resource (DAVID) in-
tegrate, in a faster computational analysis, a wide range
of enrichment analysis thought different databases pro-
viding also a substantial statistical description. The ana-
lysis was carried out considering the complete gene
space of the PPI network. We also used DAVID in order
to perform a gene ontology enrichment analysis in the
obtained clusters.
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